Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Presentation ESC 2025

Mavacamten in Symptomatic Nonobstructive Cardiomyopathy: Primary results of the ODYSSEY-HCM Trial

Presenter: Milind Y Desai

August 30, 2025

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

Caitlin E. Cox

August 30, 2025

News Daily News

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

L.A. McKeown

April 15, 2025

News Daily News

Societies Update Appropriate Use Criteria for Cardiac Implantable Devices

Todd Neale

January 23, 2025

Podcast TCTMD Talking Points

The VALOR-HCM Trial

August 02, 2023

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

Presentation ACC 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presenter: Milind Y Desai

April 03, 2022

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

News Daily News

Excluded From Trials, Patients With Severe Kidney Disease Benefit Less From TAVR

Shelley Wood

October 10, 2017

Manuscript

Role of Computed Tomography in Transcatheter Aortic Valve Replacement

September 06, 2017

News Daily News

Prior Radiation Therapy for Cancer Increases Mortality Risk After PCI

L.A. McKeown

June 21, 2016

Video

» Interview

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

April 3, 2022

Video

» Interview

Beyond the Data: VALOR-HCM

April 3, 2022

Advertisement

Mavacamten in Symptomatic Nonobstructive Cardiomyopathy: Primary results of the ODYSSEY-HCM Trial

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM

Societies Update Appropriate Use Criteria for Cardiac Implantable Devices

The VALOR-HCM Trial

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Excluded From Trials, Patients With Severe Kidney Disease Benefit Less From TAVR

Role of Computed Tomography in Transcatheter Aortic Valve Replacement

Prior Radiation Therapy for Cancer Increases Mortality Risk After PCI

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

Beyond the Data: VALOR-HCM

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content